Oral corticosteroids present significant long-term risks with uncertain evidence for improving asthma outcomes, according to data presented at the American College of Allergy, Asthma & Immunology ...

Trials of a new asthma drug show that it could prove life changing for many people – who would only need two jabs a year. The ...

The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

The MHRA has approved depemokimab as an add-on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe ...

What is Exdensur? A new FDA-approved asthma biologic from GSK that only needs two doses a year for severe eosinophilic asthma ...

GSK secures FDA approval for Exdensur, the first twice-yearly biologic for treating severe asthma with an eosinophilic phenotype.

Depemokimab-ulaa (Exdensur) has been approved by the US FDA as add-on maintenance therapy for severe asthma with an ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...

A multicentre clinical trial led by a researcher from the University of Sherbrooke will test a new therapeutic approach to moderate asthma. The study will include 150 patients, including 50 in Quebec, ...

Different blood sugar medications can cause different side effects. Learn more about some of the serious possible side effects of common diabetes medications here.

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupix ...